indaptus_logo.png
Indaptus Therapeutics to Present at Two Upcoming Investor Conferences
23 oct. 2024 08h00 HE | Indaptus Therapeutics
NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present at two upcoming investor...
indaptus_logo.png
Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations
22 oct. 2024 08h00 HE | Indaptus Therapeutics
Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus’ broadly targeted, short duration systemic immune stimulator Decoy20 expected to start in 2025...
indaptus_logo.png
Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data
15 oct. 2024 08h00 HE | Indaptus Therapeutics
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer...
indaptus_logo.png
Indaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer Immunotherapy
10 oct. 2024 08h00 HE | Indaptus Therapeutics
NEW YORK, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral...
indaptus_logo.png
Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
08 oct. 2024 08h00 HE | Indaptus Therapeutics
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will participate in a fireside chat at the...
indaptus_logo.png
Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses
05 sept. 2024 08h30 HE | Indaptus Therapeutics
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative...
indaptus_logo.png
Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
03 sept. 2024 08h00 HE | Indaptus Therapeutics
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the...
indaptus_logo.png
Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
12 août 2024 08h00 HE | Indaptus Therapeutics
NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer...
indaptus_logo.png
Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement
07 août 2024 07h00 HE | Indaptus Therapeutics
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral...
indaptus_logo.png
Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies Summit
11 juin 2024 08h00 HE | Indaptus Therapeutics
- Chief Scientific Officer Dr. Newman to present initial clinical data that further validates Company’s “Pulse-Prime” hypothesis - Dr. Newman also named Chair of the Summit NEW YORK, June 11, 2024...